Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review - Takeaways - MDSpire

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

  • By

  • Sorina Nicoleta Badelita

  • Horia Mihail Sandu

  • Daniel Coriu

  • Delia Codruta Popa

  • May 1, 2026

  • 0 min

Share

  • 1

    Bone marrow hemodilution can lead to false negative results in measurable residual disease assessments in multiple myeloma.

  • 2

    Next Generation Flow Cytometry is preferred for MRD identification due to its cost-effectiveness and ability to evaluate hemodilution.

  • 3

    Hemodilution significantly impacts MRD evaluation in multiple myeloma due to the heterogeneous distribution of plasma cells.

  • 4

    Mast cells, nucleated red blood cells, and B cell progenitors are key cellular subpopulations used to assess hemodilution.

  • 5

    A combined evaluation of multiple cellular parameters is recommended for more reliable hemodilution assessments in multiple myeloma.

Original Source(s)

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

  • by Sorina Nicoleta Badelita, Horia Mihail Sandu, Daniel Coriu, Delia Codruta Popa

  • May 1, 2026

Related Content

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms